JP2011500073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500073A5 JP2011500073A5 JP2010530432A JP2010530432A JP2011500073A5 JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5 JP 2010530432 A JP2010530432 A JP 2010530432A JP 2010530432 A JP2010530432 A JP 2010530432A JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- subunit
- sequence
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102100026720 Interferon beta Human genes 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118980 | 2007-10-22 | ||
| EP07118980.7 | 2007-10-22 | ||
| US714207P | 2007-12-11 | 2007-12-11 | |
| US61/007,142 | 2007-12-11 | ||
| PCT/EP2008/064224 WO2009053368A1 (en) | 2007-10-22 | 2008-10-21 | Single ifn-beta fused to a mutated igg fc fragment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500073A JP2011500073A (ja) | 2011-01-06 |
| JP2011500073A5 true JP2011500073A5 (enExample) | 2011-12-08 |
| JP5314033B2 JP5314033B2 (ja) | 2013-10-16 |
Family
ID=39048918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530432A Expired - Fee Related JP5314033B2 (ja) | 2007-10-22 | 2008-10-21 | 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2203180B1 (enExample) |
| JP (1) | JP5314033B2 (enExample) |
| AU (1) | AU2008314697B2 (enExample) |
| ES (1) | ES2400107T3 (enExample) |
| IL (1) | IL204948A (enExample) |
| WO (1) | WO2009053368A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534399A (en) | 2002-01-25 | 2008-08-29 | G2 Therapies Ltd | Monoclonal antibodies against extracellular loops of C5aR |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| CN104193824A (zh) | 2008-02-20 | 2014-12-10 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| US9493543B2 (en) | 2010-02-16 | 2016-11-15 | Novo Nordisk A/S | Factor VIII fusion protein |
| US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
| HRP20191305T1 (hr) | 2010-07-09 | 2019-10-18 | Bioverativ Therapeutics Inc. | Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste |
| TWI638833B (zh) * | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| CN102585013B (zh) * | 2011-01-07 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 一种含有ω干扰素的融合蛋白及制备方法 |
| PL2718322T3 (pl) * | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| WO2013011062A2 (en) * | 2011-07-18 | 2013-01-24 | Novo Nordisk A/S | Oscar antagonists |
| ES2732712T3 (es) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| KR102568808B1 (ko) | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
| SG11201609370QA (en) | 2014-05-13 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR20210013299A (ko) * | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| CN107743494B (zh) | 2015-06-02 | 2022-04-29 | 诺和诺德股份有限公司 | 具有极性重组延伸体的胰岛素 |
| EP3355931B1 (en) | 2015-10-01 | 2024-06-26 | Novo Nordisk A/S | Protein conjugates |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| DK3380522T5 (da) | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017132376A1 (en) | 2016-01-27 | 2017-08-03 | Just Biotherapeutics, Inc. | Hybrid promoter and uses thereof |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| CA3016424A1 (en) | 2016-03-14 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| MA49339A (fr) * | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CA3121699A1 (en) * | 2018-12-05 | 2020-06-11 | Morphosys Ag | Multispecific antigen-binding molecules |
| PH12021552960A1 (en) | 2019-07-10 | 2022-07-25 | Chugai Pharmaceutical Co Ltd | Claudin-6 binding molecules and uses thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20230159831A (ko) * | 2021-02-22 | 2023-11-22 | 압데라 테라퓨틱스 인크. | 표적화된 방사성 동위원소 요법을 위한 면역접합체 |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| US12600794B2 (en) | 2024-07-23 | 2026-04-14 | Abdera Therapeutics Inc. | 5T4 binding polypeptides and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100480266C (zh) * | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP2006513139A (ja) * | 2002-07-03 | 2006-04-20 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療薬の全身性送達のための中央部気道投与 |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2006207471A1 (en) * | 2005-01-24 | 2006-07-27 | Laboratoires Serona S.A. | Use of soluble CD164 variants in inflammatory and/or autoimmune disorders |
| MX2007014889A (es) * | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
-
2008
- 2008-10-21 AU AU2008314697A patent/AU2008314697B2/en not_active Ceased
- 2008-10-21 EP EP08840928A patent/EP2203180B1/en active Active
- 2008-10-21 WO PCT/EP2008/064224 patent/WO2009053368A1/en not_active Ceased
- 2008-10-21 ES ES08840928T patent/ES2400107T3/es active Active
- 2008-10-21 JP JP2010530432A patent/JP5314033B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-08 IL IL204948A patent/IL204948A/en active IP Right Revival
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thye et al. | Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis | |
| Tang et al. | Molecular medical microbiology | |
| JP2012136541A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2011528896A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| JP2010011868A5 (enExample) | ||
| JP2011528222A5 (enExample) | ||
| Villena et al. | Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of SARS-CoV-2 oral vaccines | |
| JP2010166916A5 (enExample) | ||
| JP2016512425A5 (enExample) | ||
| JP2008536483A5 (enExample) | ||
| JP2012001560A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| JP2010532656A5 (enExample) | ||
| JP2012524733A5 (enExample) | ||
| JP2013520176A5 (enExample) | ||
| JP2011528895A5 (enExample) | ||
| JP2010166921A5 (enExample) | ||
| JP2015523328A5 (enExample) | ||
| HRP20170193T4 (hr) | Izolirani polipeptid iz proteina toksina a i toksina b iz c.difficile i njegove uporabe | |
| JP2010522540A5 (enExample) | ||
| JP2011136997A5 (enExample) | ||
| JP2004533246A5 (enExample) | ||
| JP2011528897A5 (enExample) |